Cormorant Asset Management, LP 13F holdings
Cormorant Asset Management, LP reported 50 positions with a total reported value of $2.0B as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: PRAX PRAXIS PRECISION MEDICINES I (11.0%), BBOT BRIDGEBIO ONCOLOGY THERAPEUT (7.0%), PBLS PARABILIS MEDICINES INC (6.5%), RAPP RAPPORT THERAPEUTICS INC (5.7%), ERAS ERASCA INC (5.6%). Against 2026-03-31 it opened 12 new positions and exited 8. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Cormorant Asset Management, LP files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 50 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| PRAX PRAXIS PRECISION MEDICINES I | 640,000 | $214.3M | 11.0% |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 17,878,594 | $136.2M | 7.0% |
| PBLS PARABILIS MEDICINES INC | 4,615,612 | $126.3M | 6.5% |
| RAPP RAPPORT THERAPEUTICS INC | 2,657,521 | $110.7M | 5.7% |
| ERAS ERASCA INC | 6,000,000 | $109.9M | 5.6% |
| EWTX EDGEWISE THERAPEUTICS INC | 2,510,000 | $102.0M | 5.2% |
| EYPT EYEPOINT INC | 7,000,000 | $100.1M | 5.1% |
| ALMS ALUMIS INC | 3,285,596 | $92.5M | 4.7% |
| ABVX ABIVAX SA | 675,000 | $90.0M | 4.6% |
| DNTH DIANTHUS THERAPEUTICS INC | 750,000 | $73.1M | 3.7% |
| DRUG BRIGHT MINDS BIOSCIENCES INC | 900,000 | $63.2M | 3.2% |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | 3,205,433 | $62.4M | 3.2% |
| BIOA BIOAGE LABS INC | 2,390,605 | $58.6M | 3.0% |
| ORKA ORUKA THERAPEUTICS INC | 533,340 | $50.8M | 2.6% |
| ANL ADLAI NORTYE LTD | 3,978,229 | $45.7M | 2.3% |
| BBIO BRIDGEBIO PHARMA INC | 550,000 | $41.0M | 2.1% |
| TNGX TANGO THERAPEUTICS INC | 1,300,000 | $40.6M | 2.1% |
| BHVN BIOHAVEN LTD | 2,610,000 | $38.8M | 2.0% |
| AGMB AGOMAB THERAPEUTICS NV | 2,465,348 | $32.0M | 1.6% |
| MBX MBX BIOSCIENCES INC | 550,000 | $30.4M | 1.6% |
| CLYM CLIMB BIO INC | 2,106,000 | $27.5M | 1.4% |
| OLMA OLEMA PHARMACEUTICALS INC | 2,150,000 | $26.9M | 1.4% |
| DMRA DAMORA THERAPEUTICS INC | 1,000,000 | $26.0M | 1.3% |
| PHVS PHARVARIS N V | 750,000 | $25.9M | 1.3% |
| CRBP CORBUS PHARMACEUTICALS HLDGS | 2,344,971 | $22.0M | 1.1% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 12 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| PBLS PARABILIS MEDICINES INC | 4,615,612 | $126.3M | 6.5% |
| CLYM CLIMB BIO INC | 2,106,000 | $27.5M | 1.4% |
| SYRE SPYRE THERAPEUTICS INC | 225,000 | $20.0M | 1.0% |
| DFTX DEFINIUM THERAPEUTICS INC | 400,000 | $18.8M | 1.0% |
| KLRA KAILERA THERAPEUTICS INC | 550,000 | $12.1M | 0.6% |
| ELVN ENLIVEN THERAPEUTICS INC | 150,000 | $7.6M | 0.4% |
| IBIO IBIO INC | 3,570,000 | $6.2M | 0.3% |
| RACC RESEARCH ALLIANCE CORP III | 370,000 | $4.0M | 0.2% |
| ALT ALTIMMUNE INC | 1,250,000 | $3.8M | 0.2% |
| ODTX ODYSSEY THERAPEUTICS INC | 175,000 | $3.3M | 0.2% |
| BOLD BOUNDLESS BIO INC | 1,000,000 | $2.5M | 0.1% |
| QUINCE THERAPEUTICS INC | 5,498 | $100.0K | <0.1% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 8 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| CENTESSA PHARMACEUTICALS PLC | 1,050,000 | $41.7M | 2.1% |
| MAZE MAZE THERAPEUTICS INC | 750,000 | $22.4M | 1.1% |
| TERNS PHARMACEUTICALS INC | 300,000 | $15.8M | 0.8% |
| ZURA ZURA BIO LTD | 1,450,000 | $8.6M | 0.4% |
| AXSM AXSOME THERAPEUTICS INC. | 50,000 | $8.5M | 0.4% |
| GLUE MONTE ROSA THERAPEUTICS INC | 400,000 | $6.6M | 0.3% |
| RLYB RALLYBIO CORP | 400,000 | $3.6M | 0.2% |
| CNTX CONTEXT THERAPEUTICS INC | 529,550 | $1.4M | <0.1% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| BHVN BIOHAVEN LTD | 1,760,000 | 2,610,000 | +48.3% | $38.8M |
| ANL ADLAI NORTYE LTD | 2,897,857 | 3,978,229 | +37.3% | $45.7M |
| FTH FAETH THERAPEUTICS INC | 306,222 | 1,028,242 | +235.8% | $7.7M |
| ERAS ERASCA INC | 5,800,000 | 6,000,000 | +3.4% | $109.9M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| PRAX PRAXIS PRECISION MEDICINES I | 885,500 | 640,000 | -27.7% | $214.3M |
| MBX MBX BIOSCIENCES INC | 1,120,000 | 550,000 | -50.9% | $30.4M |
| EWTX EDGEWISE THERAPEUTICS INC | 3,260,000 | 2,510,000 | -23.0% | $102.0M |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | 4,480,433 | 3,205,433 | -28.5% | $62.4M |
| BBIO BRIDGEBIO PHARMA INC | 850,000 | 550,000 | -35.3% | $41.0M |
| OLMA OLEMA PHARMACEUTICALS INC | 3,900,000 | 2,150,000 | -44.9% | $26.9M |
| DNTH DIANTHUS THERAPEUTICS INC | 950,000 | 750,000 | -21.1% | $73.1M |
| ALMS ALUMIS INC | 3,949,241 | 3,285,596 | -16.8% | $92.5M |
| EYPT EYEPOINT INC | 8,265,000 | 7,000,000 | -15.3% | $100.1M |
| NAMS NEWAMSTERDAM PHARMA COMPANY | 950,000 | 500,000 | -47.4% | $16.9M |
| DMRA DAMORA THERAPEUTICS INC | 1,525,000 | 1,000,000 | -34.4% | $26.0M |
| RAPP RAPPORT THERAPEUTICS INC | 2,957,521 | 2,657,521 | -10.1% | $110.7M |
CIK 1583977 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
